A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
A phase 1/2 trial of AZD3470 and Datopotamab deruxtecan in advanced solid tumours, run by AstraZeneca, now recruiting.
Overview
A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06130553 by AstraZeneca, with 334 participants planned, started 2024-01-18 and due to reach its primary completion in 2028-12-04. Interventions recorded: AZD3470 and Datopotamab deruxtecan.
Similar pages
not linked directly; found by shared links- TrialStudy of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Shares Datopotamab deruxtecan, AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)
Shares Datopotamab deruxtecan, AstraZeneca and the tag pipeline.
- TrialOsimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialEfficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSafety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialCapivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.